We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
In this insightful interview, Dr Veronica J. Brady, 2025 President of the Association of Diabetes Care & Education Specialists (ADCES), speaks about the organization’s mission to empower diabetes care and education specialists and improve patient outcomes. Dr Brady discusses the ...
The World Alliance of Pituitary Organizations (WAPO), a leading non-profit uniting pituitary patient advocates worldwide, has announced the launch of its Blogs & Vlogs 2025, an innovative initiative designed to amplify the voices of patients, experts and advocates around the world.
Coronavirus disease 2019 (COVID-19) is a life-threatening infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1Â Diabetes mellitus is one of the most frequent comorbidities, related to hospitalization due to SARS-CoV-2 infection, as well as a risk factor for disease severity, ...
As we continue advancing the field of endocrinology, I’m excited to spotlight the impactful work being done by the American Association of Clinical Endocrinology (AACE). Our mission is to elevate the practice of clinical endocrinology to improve global health. ...
ATTD 2025 showcased 36 startups revolutionizing diabetes care with innovations like non-invasive monitoring, AI diagnostics, and real-time health tools. Awarded grants highlighted ATTD’s commitment to advancing personalized, tech-driven solutions that empower patients and transform global diabetes management.
Experts discuss optimization of multidisciplinary care of alpha-mannosidosis along the patient’s lifespan.
The 17th ATTD Conference (Amsterdam, 19–22 March 2025) showcased major innovations in diabetes care. The 15-day Dexcom G7 CGM proved accurate and user-friendly. The RADIANT trial showed Omnipod® 5 significantly improved glucose control over injections in type 1 diabetes. In type 2 diabetes, the 2IQP Study highlighted benefits of AID systems. Teplizumab also showed potential to enhance glycaemic stability in newly diagnosed type 1 diabetes, reinforcing the role of technology and immunotherapy in advancing diabetes management.
Polycystic ovary syndrome (PCOS) is a complex, multisystemic condition characterized by reproductive, metabolic and dermatologic manifestations, including hyperandrogenism and ovulatory dysfunction. Despite its prevalence and significant impact on quality of life, PCOS remains underdiagnosed and poorly managed due to its ...
Women & Diabetes takes centre stage in this interview with Zeina Abou Rizk, Founder of DiaLeb. Zeina explores the unique challenges women face in diabetes care, the power of community and advocacy, and how DiaLeb’s annual panel fosters global awareness, education, and meaningful change through lived experiences and expert insights.
Dr Linda Siminerio, a leading expert in diabetes education and healthcare delivery, shares insights from her distinguished career. Inspired by her father’s type 1 diabetes diagnosis, she has dedicated her work to improving patient education and care models. She emphasizes the importance of a team-based approach and staying ahead of technological advancements. With AI and machine learning already influencing diabetes management, she urges healthcare providers to adapt and engage with these innovations. Through her contributions, Dr Siminerio continues to shape the future of diabetes care, ensuring that patients receive the education and support they need.
Dr Svenja Nölting shares how her international experiences and dedicated mentors shaped her career in neuroendocrine oncology, discusses the profound impact of hormones on the body, and highlights the future of precision medicine in tailoring treatments for endocrine disorders.
Eneboparatide is an investigational parathyroid hormone receptor 1 (PTH1R) agonist, designed to bind with high affinity to a specific conformation of PTH1R, which is expressed in the kidneys and bone. The goal of treatment is to restore function by producing sustained and stable levels of calcium in the blood and by restoring calcium reabsorption by the kidney.2,3 Eneboparatide has been developed to have a short half-life in order to preserve bone health.
Watch four leading experts discuss how AI is transforming the clinical management of paediatric endocrine disorders including growth hormone disorders.
Hyponatraemia is primarily a disorder of water balance or distribution, characterized by serum sodium (Nas) levels less than 135 mmol/L.1 Hyponatraemia is the most common electrolyte disorder among elderly patients and is associated with increased mortality rates and longer hospital ...
Diabetes is a chronic disease associated with both acute and chronic complications. Many advances have been introduced throughout history to address these problems. While each clinical breakthrough was welcomed with relief and the expectation that a solution had been discovered, ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.